Clinical Trials Logo

Clinical Trial Summary

This retrospective study aims to describe the prevalence and clinical manifestations of different HER2 level BC by accurate reassessing of HER2 expression in archived HER2 IHC slides, and analysing clinicopathologic feature and outcomes from Fudan University Shanghai Cancer Centre (FUSCC) Breast Cancer Single Disease Database


Clinical Trial Description

This is a single-centre, retrospective study to describe the prevalence of different HER2 expression levels (HER2-high, HER2-low, HER2 Ø) in approximately 3000 breast cancer patients at FUSCC through the year of 2015. This study will collect re-assessed HER2 expression level results based on the archived HER2 IHC slides while relative demographic, treatment, clinicopathologic and efficacy data will be extracted from the FUSCC Breast Cancer Single Disease Database. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05203458
Study type Observational
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email [email protected]
Status Recruiting
Phase
Start date February 24, 2022
Completion date May 31, 2022